Breaking News Instant updates and real-time market news.

IMMY

Imprimis

$3.36

0.28 (9.09%)

, VRX

Valeant

$22.18

-0.59 (-2.59%)

08:34
10/17/16
10/17
08:34
10/17/16
08:34

Imprimis announces availability of lower-cost option for lead poison treatment

Imprimis Pharmaceuticals (IMMY) announced the availability of a significantly lower-cost compounded alternative to Valeant's (VRX) Calcium Disodium Versenate, commonly used to stabilize and treat patients exposed to lead poisoning. Imprimis' compounded EDTA calcium disodium injection is priced at $495 for a five-day treatment. According to the World Health Organization, dosing for this drug is based on blood lead levels and body surface area and can range from 1000mg to 2000mg or more daily for five days of treatment. Using Valeant's product, the estimated cost of therapy would be $27,000 for a five-day treatment. Valeant has increased the price of Calcium Disodium Versenate by over 2,700% since it acquired the drug as part of its purchase of Medicis in 2013. The original cost was $950 and it increased under Valeant's control to $7,116 in early 2014, with additional increases the same year to its current price of $27,000.

IMMY

Imprimis

$3.36

0.28 (9.09%)

VRX

Valeant

$22.18

-0.59 (-2.59%)

  • 16

    Nov

  • 14

    Dec

IMMY Imprimis
$3.36

0.28 (9.09%)

02/23/16
JMPS
02/23/16
NO CHANGE
JMPS
Retrophin well-positioned to defend Thiola franchise, says JMP Securities
After conducting checks, JMP Securities says that Retrophin is well-positioned to defend its Thiola franchise against the much cheaper, compounded version that Imprimis Pharmaceuticals (IMMY) plans to launch in April. The firm says its feedback form one expert suggests that doctors will resist using a compounded version of the product due to the risks associated with compound pharmacies, lack of issues with accessing Thiola and the ability to measure the main ingredients in Thiola. JMP keeps a $28 price target and Outperform rating on the shares.
VRX Valeant
$22.18

-0.59 (-2.59%)

09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.
10/14/16
WELS
10/14/16
NO CHANGE
WELS
Underperform
Wells says Valeant price hikes a reaction to 'disappointing' prescription trends
Wells Fargo analyst David Maris noted Valeant's announcement earlier today that the company has decided to raise prices by 2% to 9% on a broad range of products. He believes the price increases are a result of the company taking "a sobering look at disappointing prescription trends" and continues to contend that consensus estimates for Valeant in 2017 are too high. The analyst, who has kept an Underperform rating on Valeant shares since starting coverage of the stock in February, said the company's "story is the same as it has been, and the only change is in how it is being told."

TODAY'S FREE FLY STORIES

CO

China Cord Blood

$11.71

-0.33 (-2.74%)

, MRNS

Marinus Pharmaceuticals

$4.16

-0.15 (-3.48%)

08:30
09/21/17
09/21
08:30
09/21/17
08:30
Options
Three new option listings on September 21st »

New option listings for…

CO

China Cord Blood

$11.71

-0.33 (-2.74%)

MRNS

Marinus Pharmaceuticals

$4.16

-0.15 (-3.48%)

SENS

Senseonics

$3.05

0.02 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHL

Scholastic

$38.51

-0.03 (-0.08%)

08:30
09/21/17
09/21
08:30
09/21/17
08:30
Technical Analysis
Technical View: Scholastic down on wider loss and outlook »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

08:30
09/21/17
09/21
08:30
09/21/17
08:30
General news
U.S. Philly Fed index preview: »

U.S. Philly Fed index…

ALL

Allstate

$91.38

0.24 (0.26%)

08:28
09/21/17
09/21
08:28
09/21/17
08:28
Hot Stocks
Allstate reports August catastrophe loss estimate of $593M »

Allstate reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

HSIC

Henry Schein

$80.39

1.25 (1.58%)

, PDCO

Patterson Companies

$37.82

0.64 (1.72%)

08:28
09/21/17
09/21
08:28
09/21/17
08:28
Initiation
Henry Schein, Patterson Companies initiated  »

Henry Schein initiated…

HSIC

Henry Schein

$80.39

1.25 (1.58%)

PDCO

Patterson Companies

$37.82

0.64 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:25
09/21/17
09/21
08:25
09/21/17
08:25
General news
N.Y. FX Outlook »

N.Y. FX Outlook:…

BCRX

BioCryst

$5.27

-0.16 (-2.95%)

08:22
09/21/17
09/21
08:22
09/21/17
08:22
Technical Analysis
Technical View: BioCryst up on FDA news concerning Rapivab »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

MU

Micron

$35.97

0.02 (0.06%)

08:22
09/21/17
09/21
08:22
09/21/17
08:22
Recommendations
Micron analyst commentary  »

Micron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

$DJT

DJ Transportation Average

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETR

Entergy

$77.80

-0.25 (-0.32%)

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Upgrade
Entergy rating change  »

Entergy upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 05

    Nov

$DJU

DJ Utility Average

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFI

Unifi

$32.91

0.09 (0.27%)

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Conference/Events
Unifi management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IYT

iShares Transportation Average

$174.15

2.54 (1.48%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$58.81

-0.24 (-0.41%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$66.84

0.45 (0.68%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPCN

Lipocine

$4.00

0.07 (1.78%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Hot Stocks
Lipocine announces motions decision by USPTO »

Lipocine announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

08:20
09/21/17
09/21
08:20
09/21/17
08:20
General news
U.S. initial jobless claims preview: »

U.S. initial jobless…

XLY

Consumer Discretionary Sector SPDR

$89.54

0.3 (0.34%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$56.87

0.2 (0.35%)

08:19
09/21/17
09/21
08:19
09/21/17
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$53.68

-0.4 (-0.74%)

08:19
09/21/17
09/21
08:19
09/21/17
08:19
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$54.60

-0.53 (-0.96%)

08:19
09/21/17
09/21
08:19
09/21/17
08:19
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HKMPY

Hikma

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Conference/Events
Hikma has a conference call hosted by JPMorgan »

JPMorgan Analyst Gordon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XLV

Health Care Select Sector SPDR

$82.00

0.08 (0.10%)

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Conference/Events
Cowen to hold a tour »

Vehicles, Vision &…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.